The chapter explores various blood markers such as high sensitivity CRP, homocysteine, and insulin that offer insights into cardiovascular risk factors, metabolic function, and vasculature health. It challenges the traditional belief that LDL cholesterol alone determines cardiovascular risk, emphasizing the importance of considering additional markers like CAC scores and fasting insulin to comprehensively assess cardiovascular health. The conversation discusses studies on individuals with high LDL levels but low plaque burdens, questioning the linear relationship between LDL levels and plaque formation in conditions like familial hypercholesterolemia.
Today, Paul and Mike unpack their opinions about lipids. They talk about true risk for cardiovascular disease, primary versus secondary prevention, lipid lowering drugs, and share their thoughts on a recent podcast episode with Peter Attia.
*Produced by Mountain Valley Media
00:06:08 Blood markers & imaging techniques of metabolic function
00:14:38 Gene mutations
00:20:28 LDL & Plaque burden
00:27:23 Money in statins
00:31:38 Downsides of lowering LDL
01:21:23 The downsides of popular cholesterol lowering drugs
01:41:07 Should we fear heart attacks?
01:45:23 PCSK9 Inhibitors
01:52:43 Risk profile of Statins
01:53:02 Risk vs. reward of Ezetimibe
02:04:02 Primary vs. secondary prevention
Resources:
Debunking Sugar Claims: What Dr. Lustig Got Wrong On The Huberman Podcast:
https://www.youtube.com/watch?v=JcEmSgbMfco&t=2933s
Work With Mike: https://mikefave.com/